|
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 15631
© 2008 American Society of Clinical Oncology
Prognostic factors for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer
C. Herrmann,
U. Abel,
W. Stremmel,
D. Jaeger and
T. Herrmann
National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Heidelberg, Heidelberg, Germany
15631
Background: Second-line chemotherapy is widely used in advanced pancreatic cancer. However, only little data exist concerning the question which patients might benefit from second-line therapy. We intended to identify prognostic factors for time to second progression and rest survival under second-line chemotherapy of advanced pancreatic cancer. Methods: We performed a retrospective cohort study of 78 patients who started palliative chemotherapy at our department from January 2004 to June 2006 due to advanced adenocarcinoma of the pancreas. This analysis focusses on 46 patients who experienced progression under first-line therapy. Results: In multivariate analyses time to first progression below 6 months and elevated LDH at the time of diagnosis were shown to be strong and highly significant independent prognostic factors for time to second progression and residual survival. For patients with time to first progression shorter than 6 months the prognosis was poor with a median residual survival of 4.4 months versus 7.5 months for those with time to first progression of 6 months or more. Conclusions: In our cohort of patients with advanced pancreatic cancer who receive second-line chemotherapy, time to first progression below 6 months is a strong negative prognostic factor for time to second progression and residual survival.
No significant financial relationships to disclose.
|
